Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 0.80 |
| ▸ | COMT | P21964 | 7/20 | 0.80 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493648 | 0.89 | COMT (1.00) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL20100822 | 0.89 | COMT (1.00) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32669539 | 0.88 | FTO (0.81) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32669554 | 0.88 | FTO (0.85) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32669750 | 0.87 | FTO (0.60) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32670137 | 0.87 | FTO (0.80) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32669552 | 0.85 | COMT (0.62) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32669761 | 0.85 | FTO (0.77) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32669577 | 0.82 | COMT (0.60) | FTOCOMTGPR35MEN1ABCC3 | |
| SCHEMBL32669518 | 0.82 | FTO (0.54) | FTOCOMTGPR35ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024022491-A1 | FTO INHIBITORS | RPXDS CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | FTO 1/4885COMT 52/4885GPR35 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.